Advanced solid tumor Trials in Shenyang, China
Conditions / Advanced solid tumor / Shenyang, China
Advanced solid tumor has been the subject of sustained clinical investigation across multiple research sites.
32 total trials for this combination
Showing top 10 of 32 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06625593 | A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | RECRUITING | — |
| NCT06589596 | An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | RECRUITING | PHASE1 |
| NCT05981703 | A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors | RECRUITING | — |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | UNKNOWN | PHASE1/PHASE2 |
| NCT05935098 | BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors | TERMINATED | PHASE1 |
| NCT06253195 | BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT04936178 | A Study of NB003 in Patients With Advanced Malignancies | COMPLETED | PHASE1 |
| NCT06257264 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | RECRUITING | — |
| NCT06120283 | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | RECRUITING | — |
| NCT04805307 | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 | COMPLETED | PHASE1 |